BrainStorm Issues 2024 Letter to Shareholders

Provided By PR Newswire

Last update: Dec 30, 2024

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.